The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy

Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jinge, Shen, Pengfei, Sun, Guangxi, Chen, Ni, Liu, Jiandong, Tang, Xin, Huang, Rui, Cai, Diming, Gong, Jing, Zhang, Xingming, Chen, Zhibin, Li, Xiang, Wei, Qiang, Zhang, Peng, Liu, Zhenhua, Liu, Jiyan, Zeng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589665/
https://www.ncbi.nlm.nih.gov/pubmed/28903426
http://dx.doi.org/10.18632/oncotarget.19520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589665/
https://www.ncbi.nlm.nih.gov/pubmed/28903426
http://dx.doi.org/10.18632/oncotarget.19520

Ejemplares similares